Aktis Oncology, Inc. AKTS
NASDAQ · United States · Health Technology
$18.74-0.73 (-3.75%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potentia
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.